Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer
- 1 February 2008
- Vol. 71 (2) , 318-322
- https://doi.org/10.1016/j.urology.2007.08.035
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- PAI-1 and the Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Association of Adiponectin with Coronary Heart Disease and Mortality: The Rancho Bernardo StudyAmerican Journal of Epidemiology, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Role of resistin in obesity, insulin resistance and Type II diabetesClinical Science, 2005
- Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapyClinical Endocrinology, 2004
- Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClinical Science, 2003
- Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyJournal of Urology, 2002
- The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition, and Metabolic Parameters in Males with Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic HyperplasiaJournal of Urology, 1995